EcoDrugPlus

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSSAUG00010003102
Gene Symbol: FLT1
1 Cross references
198 Possible Orthologues:

Fms Related Tyrosine Kinase 4

Ensembl ID : ENSSAUG00010011154
Gene Symbol: FLT4
3 Cross references
193 Possible Orthologues:

Folate Hydrolase 1b

Ensembl ID : ENSSAUG00010010665
Gene Symbol: FOLH1B
3 Cross references
339 Possible Orthologues:

Folate Receptor Beta-Like

Ensembl ID : ENSSAUG00010010866
Gene Symbol: LOC115569735
3 Cross references
436 Possible Orthologues:

Free Fatty Acid Receptor 2-Like

Ensembl ID : ENSSAUG00010023503
Gene Symbol: LOC115567910
2 Cross references
338 Possible Orthologues:

Free Fatty Acid Receptor 3-Like

Ensembl ID : ENSSAUG00010027148
Gene Symbol: LOC115578489
3 Cross references
320 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSSAUG00010005174
Gene Symbol: FRK
3 Cross references
202 Possible Orthologues:

Galactosidase Alpha

Ensembl ID : ENSSAUG00010019371
Gene Symbol: GLA
3 Cross references
196 Possible Orthologues:

Galectin-3-Like

Ensembl ID : ENSSAUG00010025389
Gene Symbol: LOC115597648
3 Cross references
219 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-1-Like

Ensembl ID : ENSSAUG00010018587
Gene Symbol: LOC115593901
3 Cross references
200 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-2-Like

Ensembl ID : ENSSAUG00010023789
Gene Symbol: LOC115568892
2 Cross references
200 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Alpha4 Subunit

Ensembl ID : ENSSAUG00010023787
Gene Symbol: GABRA4
3 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).